July could be a good time to put fresh money to work on the ASX.
If I had $10,000 to invest in ASX 200 shares this month, I would want a mix of global growth, specialist technology, and businesses with long runways.
Here are three shares I would consider buying.
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
I would start with Breville. An investment in the appliance company could give investors exposure to a business that has taken ordinary kitchen categories and turned them into premium global products.
Breville is best known for coffee machines, cooking appliances, food preparation products, and other household equipment.
The reason it stands out is that its products are often tied to habits, not just purchases. A coffee machine can become part of the morning routine, while cooking products can sit at the centre of how people prepare food at home.
That gives the brand more depth than a simple appliance label.
Breville is still exposed to consumer spending cycles, and premium products can face pressure when households become cautious. But its global footprint, strong product design, and brand positioning give it a long runway if management keeps executing well.
Hub24 Ltd (ASX: HUB)
Another top ASX 200 share to buy could be Hub24.
The company operates an investment and superannuation platform used by financial advisers to manage client portfolios, reporting, administration, and investment options.
This is not the most obvious growth story on the ASX, but it is an important one. Australia has a large and growing pool of wealth sitting in superannuation and investment accounts. Advisers need better technology to manage that money, and clients increasingly expect clearer reporting, broader choice, and more efficient administration.
Hub24 has been taking market share from older platform providers by offering a more modern service to advisers and wealth professionals.
Competition remains a risk, and platform margins can attract pressure over time. But if the company keeps winning advisers and attracting funds, it could continue benefiting from one of the biggest structural tailwinds in Australian finance.
Pro Medicus Ltd (ASX: PME)
Finally, Pro Medicus could be an ASX 200 share to buy with the funds.
Pro Medicus is one of the ASX's highest-quality software shares. Its Visage imaging platform is used by hospitals and radiology groups to view, manage, and distribute medical images across large healthcare networks.
The business solves a problem that is becoming more demanding. Medical scans are getting larger, imaging volumes continue to rise, and healthcare providers need systems that can move quickly across complex environments.
That is where Pro Medicus has built its reputation. Its contracts can be large, long term, and difficult to displace once the software is embedded inside hospital workflows.
The main risk is valuation. Pro Medicus often trades on high expectations, which means any disappointment can hit the share price hard.
But as a long-term holding, its mix of healthcare demand, specialist software, and global expansion potential remains compelling.
